Cardiac Ablation Market - By Product (Radiofrequency (RF), Ablators, Electrical Ablators, Cryoablation Devices, Ultrasound Ablators), By Approach (Catheter-Based, Open/Surgical), By Application, By End-use & Forecast, 2023 - 2032
Published on: 2024-08-02 | No of Pages : 240 | Industry : Healthcare
Publisher : MIR | Format : PDF&Excel
Cardiac Ablation Market - By Product (Radiofrequency (RF), Ablators, Electrical Ablators, Cryoablation Devices, Ultrasound Ablators), By Approach (Catheter-Based, Open/Surgical), By Application, By End-use & Forecast, 2023 - 2032
Cardiac Ablation Market Size
Cardiac Ablation Market size was valued at over USD 3.5 billion in 2022 and is projected to observe over 13.5% CAGR between 2023 to 2032.
High caffeine intake, adoption of a sedentary lifestyle, overconsumption of alcohol and tobacco, substance abuse, and smoking habits are factors that are likely to contribute to increasing occurrences of cardiac ailments. As per WHO, over 1.9 million people across the world die due to tobacco-related cardiac disorders each year. Other estimates from the American Heart Association (AHA) suggest that cardiovascular ailments account for nearly 800,000 U.S. deaths annually, of which 20% of cases are due to cigarette smoking.
Report Attribute | Details |
---|---|
Base Year | 2022 |
Cardiac Ablation Market Size in 2022 | 3.5 Billion (USD) |
Forecast Period | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR | 13.5% |
2032 Value Projection | 14.5 Billion (USD) |
Historical Data for | 2018 to 2022 |
No. of Pages | 175 |
Tables, Charts & Figures | 262 |
Segments covered | Product, Approach, Application, End-use, and Region |
Growth Drivers |
|
Pitfalls & Challenges |
|
High cardiac ablation-related risks may constrain industry development
In the short run, the risks related to cardiac ablation procedures may hinder cardiac ablation market progress. Some of the cardiac ablation surgery-related risks include infections, damage to blood vessels, and pulmonary stenosis. Moreover, a rare complication associated with catheter-based ablation is the development of an atrial-esophageal fistula and esophageal injury is likely to affect patient preference for the procedure. As per the Journal of AHA, 1 in 18 patients undergoing atrial fibrillation ablation encountered a procedural complication within 30 days of hospital discharge with bleeding and pericardial effusion.
Cardiac Ablation Market Analysis
Based on product, the cardiac ablation market is divided into cryoablation devices, ultrasound ablators, electrical ablators, radiofrequency (RF) ablators, and others. The electrical ablators segment is anticipated to record a 14% CAGR from 2023 to 2032. Increasing R&D efforts for bringing advanced therapeutic procedures to treat chronic cardiac disorders is anticipated to expand product development. Moreover, the consistent development of surgical technologies for replacing traditional treatments is likely to spur segment expansion.
cardiac ablation market from open/surgical approach segment held over USD 960 million in 2022. These procedures are used for the treatment of atrial fibrillation and other CVDs. As per the Heart and Stroke Foundation, approximately 25% of all stroke cases after 40 years are due to atrial fibrillation which depicts its high occurrence. Rising prevalence of atrial fibrillation should boost the uptake of open/surgical procedures, which is likely to propel segment outlook.
Cardiac ablation market share from the tachycardia segment is expected to record over 14.5% CAGR from 2023 to 2032. The increasing number of patients suffering from tachycardia has risen considerably over recent years. Strenuous exercise or stress are some of the factors that can led to unusual rise in heart rate. As per CDC, tachycardia affects nearly 1 in every 300 people in the U.S. The condition is mainly occurring amongst the elderly and female population.
With respect to end-use, the industry is segmented into ambulatory surgical centers, cardiac centers, hospitals, and others. Amongst them, the cardiac centers segment is likely to hold over 20% market share by 2032. These centers are increasingly deployed across developing economies as it offers advanced treatment alternatives. The need for more effective treatment solutions should increase patient footfall across these centers. Moreover, cardiac centers also offer preliminary care and adequate treatment to patients undergoing cardiac ablation procedures, which may complement segment growth.
Europe cardiac ablation market is poised to reach over USD 4 billion by 2032. Rising adoption of innovative technologies in the health care sector coupled with increasing per capita income in the region is expected to support this share. The demand for cardiac ablation devices can also increase in the region given to the presence of the elderly population that is highly susceptible to various chronic diseases.
Cardiac Ablation Market Share
Some of the leading companies in the global market include
- Abbott Laboratories
- Medtronic
- Biosense Webster (Johnson & Johnson)
- Angiodynamics
- Boston Scientific Corporation
- Atricure
- Japan Lifeline
Many of these companies are focusing on mergers and acquisition strategies to extend their business footprint.
Impact of COVID-19 Pandemic
The COVID-19 pandemic had a negative impact on the cardiac ablation industry due to movement constraints caused by the stringent lockdown. Atrial fibrillation (AF) ablation services were severely influenced by the pandemic. Typically, catheter ablation procedures for atrial fibrillation were curtailed to contain the spread of the virus. However, the market is likely to revive given to a substantial decrease in the number of COVID-19 cases.
The cardiac ablation market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032 for the following segments
Click here to Buy Section of this Report
By Product
- Radiofrequency (RF)
- Ablators
- Electrical ablators
- Cryoablation devices
- Ultrasound ablators
- Others
By Approach
- Catheter-based
- Open/Surgical
By Application
- Atrial fibrillation & flutter
- Tachycardia
- Others
By End-use
- Hospitals
- Ambulatory surgical centers
- Cardiac centers
- Others
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Russia
- Others
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Others
- Latin America
- Brazil
- Mexico
- Argentina
- Others
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Others